Great Lakes Clinical Trials Initiates Early-Stage Alzheimer's Study Targeting Tau Proteins

A clinical research study is ongoing to study the effects of an investigational Anti-Tau antibody called ABBV-8E12 in patients with early stage Alzheimer's disease.

The progression of abnormal Tau proteins in the brain is strongly associated with clinical progression of disease and resulting decline in brain function. 

The video below describes the science behind this novel approach to targeting the source of Alzheimer's disease.

If you are interested in learning more about this research study, call our Patient Care Representatives at (773) 275-3500 or click HERE to visit our study webpage.